DHHS → node
On October 19, 2022, the Food and Drug Administration (FDA) reissued an Emergency Use Authorization letter (EUA) for the use of Monovalent COVID-19 vaccine booster doses from Novavax.
On Monday, November 7, 2022, Kepro will upgrade their web-based platform to Atrezzo Next Generation. The Atrezzo Next Generation (ANG) platform is an improved interface with enhanced security features such as Multi-Factor Authentication (MFA).
Training Plan and Resources
Pursuant to Public Law 2021 Chapter 639, the Department must annually develop a schedule of rate determination in consultation with the MaineCare Rate Reform Expert Technical Advisory Panel (TAP). The Department must then post the proposed rate determination schedule on its publicly accessible website, provide an opportunity for the public to review and comment on the rate determination schedule, and make available a summary of these comments on its publicly accessible website.
In response to comments submitted during the public comment period for the recently adopted Section 25, Dental Services and Reimbursement Methodology rulemaking, the Department indicated that it would pursue system changes to waive prior authorization (PA) requirements for crowns in qualifying circumstances.
A message sent on October 12, 2022, to providers participating in the 340B Drug Program did not identify a contact person for providers with questions.
Please reach out to Shannon Beggs of Provider Relations for any questions related to the 340B Drug Program.
Pursuant to PL 2021, ch.
Oct 10, 2022
The Maine Department of Health and Human Services (DHHS) remains committed to improving operations to better serve and meet the needs of Maine people. A major component of these efforts is leveraging technologies to upgrade outdated systems, transition paper-based processes online, improve customer service, increase transparency, and inform data-driven policies and service delivery.
The Department has completed several major technology projects to improve access to services and benefits for Maine people, including:
This bulletin provides notice that the Department has initiated a Rate Determination Process* for Section 107 Psychiatric Residential Treatment Facility Services of the MaineCare Benefits Manual. MaineCare’s Rate Setting Unit will be conducting this rate determination. The newly determined rates will update MaineCare reimbursement for this service to better align with reimbursement for related services, consistent with the Department’s reimbursement reform process.
In an October 12, 2022, announcement, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUA) for the use of Bivalent COVID-19 vaccines from Pfizer BioN-Tech for ages five years and older, and Moderna for ages six years and older, as a booster dose